Pulmatrix, Inc.PULM
Price (close)
$1.67
Market cap
$6.1M
P/E
—
Revenue (TTM)
—
Net income
-$4.0M
Dividend yield
—
1-year total return
-62.1%
Net margin
—
Revenue growth
—
Debt / equity
—
What Pulmatrix, Inc. does.
are a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat
migraine and respiratory diseases with important unmet medical needs using our patented iSPERSE ™ technology. Our proprietary
product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $5.2M | $6.1M | $7.3M | $7.8M | — |
| Net income | -$19.3M | -$20.2M | -$18.8M | -$14.1M | -$9.6M | -$5.2M |
| Free cash flow | -$12.8M | -$19.9M | -$19.4M | -$16.7M | -$11.1M | — |
More on PULM.
- Pulmatrix, Inc. summary
- Pulmatrix, Inc. financial statements
- Pulmatrix, Inc. key metrics
- Pulmatrix, Inc. health scores and style box
- Pulmatrix, Inc. earnings
- Pulmatrix, Inc. dividends
- Pulmatrix, Inc. valuation
- Pulmatrix, Inc. ownership and insiders
- Pulmatrix, Inc. peers
Figures from Pulmatrix, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.